Gene Therapy | 基因治疗

📚 Gene Therapy | 基因治疗

Gene therapy is an experimental technique that uses genes to treat or prevent disease. It aims to correct defective genes responsible for disease development by inserting a functional copy of the gene, repairing the faulty gene, or introducing a new gene to help fight a disorder. This approach holds promise for the treatment of a wide range of inherited disorders, certain cancers, and viral infections.

基因治疗是一种利用基因来治疗或预防疾病的实验性技术。它旨在通过插入功能正常的基因副本、修复有缺陷的基因，或引入新基因来帮助对抗疾病，从而纠正导致疾病发生的缺陷基因。这一方法有望用于治疗多种遗传病、某些癌症和病毒感染。

1. Overview of Gene Therapy | 基因治疗概述

Gene therapy relies on the delivery of therapeutic nucleic acids into a patient’s cells. The introduced genetic material can replace a missing or non-functional gene, silence a harmful gene, or even prime the immune system to recognise and destroy cancer cells. Unlike conventional treatments that manage symptoms, gene therapy addresses the root genetic cause of a disease.

基因治疗依赖于将治疗性核酸递送到患者细胞内。引入的遗传物质可以替代缺失或无功能的基因，沉默有害基因，甚至能让免疫系统识别并消灭癌细胞。与仅控制症状的常规治疗不同，基因治疗针对的是疾病的根本遗传原因。

The first approved gene therapy trial took place in 1990, treating a four-year-old girl with adenosine deaminase (ADA) deficiency, a form of severe combined immunodeficiency (SCID). Since then, significant advances have been made, and several gene therapies have received regulatory approval worldwide, though challenges remain in terms of safety and long-term efficacy.

首个获批的基因治疗临床试验于1990年进行，治疗了一名患有腺苷脱氨酶（ADA）缺乏症（一种重症联合免疫缺陷）的四岁女孩。此后，该领域取得了显著进展，多种基因疗法已获得全球监管机构的批准，但在安全性和长期疗效方面仍存在挑战。

2. Somatic vs. Germline Gene Therapy | 体细胞与生殖细胞基因治疗

Somatic gene therapy involves introducing therapeutic genes into the somatic (body) cells of a patient. These genetic changes are not passed on to the patient’s offspring. This form of gene therapy is the only type currently permitted in human clinical trials due to ethical and safety considerations.

体细胞基因治疗是将治疗性基因导入患者的体细胞（身体细胞）。这些基因改变不会遗传给患者的后代。由于伦理和安全方面的考虑，这是目前人类临床试验中唯一被允许的类型。

Germline gene therapy targets the reproductive cells—sperm, eggs, or early embryos—such that the genetic modification is heritable and will be present in every cell of the resulting individual and subsequent generations. Although it could theoretically eliminate inherited diseases permanently, germline gene therapy is prohibited in many countries because of profound ethical concerns and unforeseen long-term consequences.

生殖细胞基因治疗以生殖细胞（精子、卵子或早期胚胎）为目标，使得基因修饰能够遗传，并出现在发育成的个体及其后代的每一个细胞中。尽管从理论上讲可以永久消除遗传病，但出于深刻的伦理担忧和不可预见的长期后果，许多国家禁止生殖细胞基因治疗。

3. Ex Vivo and In Vivo Approaches | 离体与体内基因治疗方法

In an ex vivo approach, target cells are removed from the patient, genetically modified in the laboratory, and then transplanted back into the patient. This strategy is particularly suitable for cells that can be easily harvested and returned, such as hematopoietic stem cells used in the treatment of blood disorders like SCID and beta-thalassemia.

在离体方法中，先将靶细胞从患者体内取出，在实验室中进行基因修饰，然后移植回患者体内。该策略特别适合易于获取和回输的细胞，例如用于治疗SCID和β-地中海贫血等血液病的造血干细胞。

In vivo gene therapy delivers the therapeutic gene directly into the patient’s body, targeting the affected tissues or organs. The gene vector is often administered via injection into the bloodstream, eye, or specific organ. This approach is used for disorders where cells cannot be easily removed and replaced, such as cystic fibrosis affecting the lungs, or retinal dystrophies in the eye.

体内基因治疗是将治疗性基因直接递送到患者体内，靶向受影响的组织或器官。基因载体通常通过注射到血液、眼睛或特定器官中给药。这种方法用于细胞不易取出和回输的疾病，例如影响肺部的囊性纤维化或眼部的视网膜营养不良。

4. Viral Vectors for Gene Delivery | 用于基因递送的病毒载体

Viruses have evolved to efficiently transfer their genetic material into host cells, making them ideal vehicles for gene delivery. In gene therapy, viral genomes are modified to remove disease-causing genes and to incorporate the therapeutic gene, allowing safe and targeted delivery. The most commonly used viral vectors include retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses (AAVs).

病毒经过进化，能够高效地将自身遗传物质转入宿主细胞，使其成为理想的基因递送载体。在基因治疗中，病毒基因组被改造以去除致病基因并整合治疗性基因，从而实现安全、定向的递送。最常用的病毒载体包括逆转录病毒、慢病毒、腺病毒和腺相关病毒（AAV）。

Retroviruses, such as murine leukaemia virus, integrate their RNA (reverse transcribed into DNA) into the host genome, enabling stable, long-term expression in dividing cells. However, this integration can occur near oncogenes, posing a risk of insertional mutagenesis and leukaemia, as observed in early SCID-X1 trials.

逆转录病毒（如鼠白血病病毒）将其RNA（逆转录为DNA）整合到宿主基因组中，从而在分裂细胞中实现稳定、长期的表达。然而，这种整合可能发生在原癌基因附近，带来插入突变和白血病的风险，正如早期SCID-X1试验中所观察到的那样。

Adeno-associated viruses (AAVs) are non-pathogenic and generally do not integrate into the host genome, instead persisting as episomes. They elicit a mild immune response and can transduce both dividing and non-dividing cells, making them a leading choice for in vivo gene therapy in tissues such as the retina, liver, and central nervous system.

腺相关病毒（AAV）无致病性，通常不整合到宿主基因组中，而是以游离基因体的形式存在。它们引起的免疫反应较弱，并能转导分裂和非分裂细胞，因此成为针对视网膜、肝脏和中枢神经系统等组织进行体内基因治疗的首选载体。

5. Non-Viral Delivery Methods | 非病毒递送方法

Non-viral vectors offer advantages in terms of safety, low immunogenicity, and ease of production. They avoid the risk of insertional mutagenesis associated with integrating viruses. Common non-viral methods include the direct injection of naked plasmid DNA, the use of lipid-based nanoparticles (liposomes) to encapsulate and protect the DNA, and physical techniques such as electroporation and gene guns.

非病毒载体具有安全性高、免疫原性低和易于生产等优势。它们避免了整合病毒相关的插入突变风险。常见的非病毒方法包括直接注射裸质粒DNA、使用脂质纳米颗粒（脂质体）封装并保护DNA，以及电穿孔和基因枪等物理技术。

Lipid nanoparticles (LNPs) have gained prominence with the success of mRNA vaccines and are now being explored for gene therapy applications. They can efficiently deliver mRNA or DNA payloads into cells via endocytosis. However, non-viral vectors typically achieve lower transfection efficiency and transient gene expression compared to viral vectors, limiting their use in conditions requiring sustained protein production.

脂质纳米颗粒（LNP）随着mRNA疫苗的成功而崭露头角，现正被探索用于基因治疗。它们能通过内吞作用有效地将mRNA或DNA有效载荷递送入细胞。然而，与病毒载体相比，非病毒载体的转染效率通常较低，基因表达是瞬时的，限制了它们在需要持续产生蛋白质的疾病中的应用。

6. Gene Replacement and Gene Augmentation | 基因置换与基因增强

Gene replacement therapy is the most straightforward form of gene therapy and is designed for recessive monogenic disorders caused by a loss-of-function mutation. A functional copy of the defective gene is delivered into target cells, enabling the production of the missing or non-functional protein. Cystic fibrosis, caused by mutations in the CFTR gene, was one of the earliest targets for gene replacement therapy via aerosolised viral vectors to the lungs.

基因置换治疗是最直接的一种基因治疗形式，适用于由功能缺失突变引起的隐性单基因遗传病。将缺陷基因的功能正常副本递送到靶细胞中，使缺失或无功能的蛋白得以产生。由CFTR基因突变引起的囊性纤维化，是通过雾化病毒载体向肺部递送基因来进行基因置换治疗的最早靶点之一。

Gene augmentation introduces a therapeutic gene that adds a new function to the target cells, often used in cancer therapy. For example, the introduction of the tumour suppressor gene p53 into cancer cells can induce apoptosis or enhance sensitivity to chemotherapy. Similarly, ‘suicide gene’ therapy delivers a gene encoding an enzyme that converts a non-toxic prodrug into a cytotoxic agent, selectively killing cancer cells.

基因增强是导入一个可增加靶细胞新功能的治疗性基因，常用于癌症治疗。例如，将抑瘤基因p53导入癌细胞可以诱导细胞凋亡或增强对化疗的敏感性。类似地，”自杀基因”疗法通过递送编码酶的基因，将无毒前药转化为细胞毒性剂，选择性地杀死癌细胞。

7. Gene Silencing and RNA Interference | 基因沉默与RNA干扰

In some diseases, a mutant gene produces a toxic protein or an overactive protein that needs to be suppressed. Gene silencing strategies, such as RNA interference (RNAi), use small interfering RNA (siRNA) or short hairpin RNA (shRNA) molecules to bind to the target mRNA and trigger its degradation, thereby preventing translation into the harmful protein.

在某些疾病中，突变基因会产生有毒蛋白质或过度活跃的蛋白质，需要被抑制。基因沉默策略，如RNA干扰（RNAi），利用小干扰RNA（siRNA）或短发夹RNA（shRNA）分子来结合靶mRNA并引发其降解，从而阻止其翻译成有害蛋白质。

Antisense oligonucleotides (ASOs) are short, single-stranded DNA or RNA molecules that hybridise to target mRNA and block translation or alter splicing. ASO therapies have been approved for spinal muscular atrophy (nusinersen) and Duchenne muscular dystrophy (eteplirsen), demonstrating the clinical potential of gene silencing without altering the patient’s genome.

反义寡核苷酸（ASO）是短的、单链DNA或RNA分子，可与靶mRNA杂交并阻断翻译或改变剪接。ASO疗法已被批准用于脊髓性肌萎缩症（nusinersen）和杜氏肌营养不良症（eteplirsen），表明在不改变患者基因组的情况下进行基因沉默具有临床潜力。

8. Gene Editing: CRISPR-Cas9 and Beyond | 基因编辑：CRISPR-Cas9及其它技术

Gene editing represents a transformative advancement, enabling precise modification of the genome at a specific locus. The CRISPR-Cas9 system, derived from a bacterial immune mechanism, uses a guide RNA to direct the Cas9 endonuclease to a complementary DNA sequence, creating a double-strand break. The cell’s repair machinery then introduces insertions or deletions (indels) that can knock out a gene, or a provided donor DNA template can be used to correct a mutation via homology-directed repair (HDR).

基因编辑是一种变革性进步，能在基因组的特定位置进行精确修饰。源自细菌免疫机制的CRISPR-Cas9系统，利用导向RNA将Cas9核酸内切酶引导至互补的DNA序列，产生双链断裂。细胞的修复机制随后引入插入或缺失突变，从而敲除基因；或者，提供供体DNA模板，通过同源定向修复（HDR）来纠正突变。

The potential of CRISPR-Cas9 extends to correcting point mutations in sickle cell disease, disrupting the CCR5 receptor to confer HIV resistance, and engineering T cells for cancer immunotherapy. More recent tools like base editors and prime editors allow single-nucleotide changes without inducing double-strand breaks, reducing off-target effects and enhancing safety for therapeutic applications.

CRISPR-Cas9的潜力扩展到纠正镰状细胞病的点突变、破坏CCR5受体以赋予HIV抵抗力，以及改造T细胞用于癌症免疫治疗。更新的工具如碱基编辑器和先导编辑器，允许在无需诱导双链断裂的情况下进行单核苷酸改变，降低了脱靶效应，提高了治疗应用的安全性。

9. Case Study: ADA-SCID and SCID-X1 | 案例研究：ADA-SCID与SCID-X1

Severe combined immunodeficiency (SCID) disorders are among the most compelling examples of successful gene therapy. ADA-SCID is caused by a deficiency of the adenosine deaminase enzyme, leading to toxic accumulation of metabolites that destroy lymphocytes. Pioneering ex vivo gene therapy involved harvesting the patient’s bone marrow stem cells, transducing them with a retroviral vector carrying the ADA gene, and reinfusing the corrected cells.

重症联合免疫缺陷（SCID）疾病是基因治疗成功最有力的例子之一。ADA-SCID由腺苷脱氨酶缺乏引起，导致有毒代谢物积累并破坏淋巴细胞。开创性的离体基因治疗涉及采集患者的骨髓干细胞，用携带ADA基因的逆转录病毒载体转导这些细胞，再回输修正后的细胞。

SCID-X1, the most common form of SCID, results from mutations in the IL2RG gene encoding the common gamma chain of interleukin receptors. Early gene therapy trials restored immune function in most patients, but several developed leukaemia due to vector integration near the LMO2 proto-oncogene. This prompted the development of safer self-inactivating lentiviral vectors with improved configuration to minimise the risk of insertional mutagenesis.

SCID-X1是SCID最常见的形式，由编码白细胞介素受体共同γ链的IL2RG基因突变引起。早期的基因治疗试验恢复了大多数患者的免疫功能，但有几名患者因载体整合在LMO2原癌基因附近而患上白血病。这促使开发出更安全的自身失活型慢病毒载体，其改良的结构可最大限度地降低插入突变的风险。

10. Challenges and Risks in Gene Therapy | 基因治疗的挑战与风险

Despite remarkable progress, gene therapy faces significant technical and biological hurdles. The immune response against the viral vector or the newly expressed protein can neutralise the therapeutic effect or cause inflammation and organ damage. Pre-existing immunity to AAV capsids is a particular concern, often excluding many potential patients from AAV-based trials.

尽管取得了显著进展，基因治疗仍面临重大的技术和生物学障碍。针对病毒载体或新表达蛋白的免疫反应可能中和治疗效果，或引起炎症和器官损伤。对AAV衣壳的预先免疫是一个特别值得关注的问题，常常将许多潜在患者排除在基于AAV的试验之外。

Insertional mutagenesis remains a risk with integrating vectors. Other limitations include transient gene expression in non-integrating approaches, difficulty in targeting specific cell types, and the high cost of production of clinical-grade vectors. Ensuring sustained, appropriate levels of gene expression without disturbing normal cellular regulation is a complex balancing act.

插入突变仍是整合型载体的风险。其他限制包括非整合方法中短暂的基因表达、特定细胞类型的靶向困难，以及临床级载体的高昂生产成本。在不干扰正常细胞调控的情况下确保持续、适当的基因表达水平，是一项复杂的平衡工作。

11. Ethical and Social Considerations | 伦理与社会考量

Gene therapy raises profound ethical questions, especially concerning germline interventions. The prospect of ‘designer babies’ with selected genetic traits touches on eugenics and equity issues. An international consensus largely prohibits germline gene editing for reproductive purposes, as heritable changes could have unpredictable effects on future generations and would be made without the consent of those affected.

基因治疗引发了深刻的伦理问题，尤其是涉及生殖细胞干预时。”设计婴儿”的可能，即具有选定遗传特征的婴儿，触及优生学和公平性问题。国际共识在很大程度上禁止以生殖为目的的生殖细胞基因编辑，因为可遗传的改变可能对后代产生不可预测的影响，并且是在未征得受影响者同意的情况下进行的。

In somatic gene therapy, ethical oversight focuses on informed consent, risk-benefit assessment, and equitable access to expensive therapies. The high cost of approved gene therapies—sometimes exceeding a million dollars per patient—creates disparities in healthcare. Regulatory frameworks strive to ensure that trials are conducted transparently and that vulnerable populations are protected from exploitation.

在体细胞基因治疗中，伦理监督侧重于知情同意、风险-获益评估以及昂贵疗法的公平可及。已获批基因疗法的高昂成本——有时每位患者超过一百万美元——造成了医疗保健方面的不平等。监管框架致力于确保试验的透明进行，并保护弱势群体免受剥削。

12. Future Perspectives and Personalised Medicine | 未来展望与个性化医疗

The future of gene therapy lies in improving vector specificity, reducing toxicity, and combining gene editing with stem cell technology to create durable cures. Advances in non-viral delivery, such as targeted nanoparticles and in vivo CRISPR delivery, are expanding the range of treatable conditions to include metabolic diseases, neurodegenerative disorders, and many cancers.

基因治疗的未来在于提高载体特异性、降低毒性，并将基因编辑与干细胞技术相结合，以创造持久的治愈方法。非病毒递送的进步，如靶向纳米颗粒和体内CRISPR递送，正在扩大可治疗疾病的范围，包括代谢性疾病、神经退行性疾病和多种癌症。

Personalised gene therapy, where a patient’s own cells are genetically corrected and returned, is becoming more feasible with automated manufacturing and improved gene editing precision. The integration of genomic sequencing data with therapy design paves the way for truly individualised medicine, moving beyond ‘one size fits all’ approaches to target the unique molecular signature of each patient’s disease.

个性化的基因治疗——即对患者自身细胞进行基因修正后回输——正随着自动化制造和基因编辑精准度的提升而变得更加可行。基因组测序数据与治疗方案设计的结合，为真正的个体化医疗铺平了道路，超越了”一刀切”模式，针对每位患者疾病的独特分子特征进行治疗。

Published by TutorHao | Biology Revision Series | aleveler.com

更多咨询请联系16621398022（同微信）

Gene Therapy | 基因治疗